Literature DB >> 12204789

Synthetic cervical mucus formulation.

Bríd T Burruano1, Roger L Schnaare, Daniel Malamud.   

Abstract

A synthetic formulation has been developed with viscosity, spinnbarkeit, and pH comparable to that reported for human cervical mucus. The formulation contains guar gum crosslinked with borate ion, mucin (dried porcine gastric), and a mixed preservative system in pH 7.4, 0.1M phosphate buffer. The guar gum source, mucin concentration, and method of preparation were shown to be critical factors in the performance of the formulation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12204789     DOI: 10.1016/s0010-7824(02)00336-0

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  11 in total

1.  In vitro test to evaluate the interaction between synthetic cervical mucus and vaginal formulations.

Authors:  Bríd T Burruano; Roger L Schnaare; Daniel Malamud
Journal:  AAPS PharmSciTech       Date:  2004-03-12       Impact factor: 3.246

Review 2.  Vaginal drug delivery systems for HIV prevention.

Authors:  Lisa Cencia Rohan; Alexandra B Sassi
Journal:  AAPS J       Date:  2009-02-05       Impact factor: 4.009

3.  Establishment of a Mucin Secreting Cell Line Cx-03 from an Uterine Carcino Sarcoma.

Authors:  R Bücker; C Schaefer; A D Gruber; J Hoppe; L Lazzerini; J Barinoff; J Sehouli; Günter Cichon
Journal:  Pharm Res       Date:  2018-11-08       Impact factor: 4.200

4.  An adsorption chromatography assay to probe bulk particle transport through hydrogels.

Authors:  I Vladescu; O Lieleg; S Jang; Katharina Ribbeck
Journal:  J Pharm Sci       Date:  2011-09-08       Impact factor: 3.534

Review 5.  Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs.

Authors:  Jill M Steinbach
Journal:  Cell Mol Life Sci       Date:  2014-10-17       Impact factor: 9.261

6.  Human immunodeficiency virus type 1 nucleocapsid inhibitors impede trans infection in cellular and explant models and protect nonhuman primates from infection.

Authors:  Gregory S Wallace; Cecilia Cheng-Mayer; Marco L Schito; Patricia Fletcher; Lisa M Miller Jenkins; Ryo Hayashi; A Robert Neurath; Ettore Appella; Robin J Shattock
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

7.  Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.

Authors:  P Fletcher; S Harman; H Azijn; N Armanasco; P Manlow; D Perumal; M-P de Bethune; J Nuttall; J Romano; R Shattock
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191

8.  Analgesic activity of a polysaccharide in experimental osteoarthritis in rats.

Authors:  Rondinelle Ribeiro Castro; Judith Pessoa Andrade Feitosa; Pablyana Leila Rodrigues da Cunha; Francisco Airton Castro da Rocha
Journal:  Clin Rheumatol       Date:  2007-01-11       Impact factor: 3.650

Review 9.  The Pre-clinical Toolbox of Pharmacokinetics and Pharmacodynamics: in vitro and ex vivo Models.

Authors:  Carolina Herrera
Journal:  Front Pharmacol       Date:  2019-05-24       Impact factor: 5.810

10.  Efficacy of silk fibroin biomaterial vehicle for in vivo mucosal delivery of Griffithsin and protection against HIV and SHIV infection ex vivo.

Authors:  Katti R Crakes; Carolina Herrera; Jessica L Morgan; Katie Olstad; Ann J Hessell; Paul Ziprin; Patricia J LiWang; Satya Dandekar
Journal:  J Int AIDS Soc       Date:  2020-10       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.